Should we optimise or revise the management of initially unresectable stage III non-small cell lung cancer: rethinking consolidation therapy
Journal of the National Cancer Center · 2026-08 · 6 (4) · 329-344
DOI: 10.1016/j.jncc.2026.04.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the National Cancer Center, 2026-08. Verfasst von Hassan Abdelilah Tafenzi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Mohammed VI University Hospital of Marrakech, Marrakech, Morocco. Die Arbeit nennt 198 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Oncology Department, Mohammed VI University Hospital of Marrakech, Marrakech, Morocco.
- Biosciences and Health Laboratory, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco.
- Medical Oncology Department, Avicenna Military Hospital of Marrakech, Marrakech, Morocco.
Zitieren
APA
Tafenzi, H. A., Essadi, I., & Belbaraka, R. (2026). Should we optimise or revise the management of initially unresectable stage III non-small cell lung cancer: rethinking consolidation therapy. Journal of the National Cancer Center, 6(4), 329-344. https://doi.org/10.1016/j.jncc.2026.04.006
Vancouver
Tafenzi HA, Essadi I, Belbaraka R. Should we optimise or revise the management of initially unresectable stage III non-small cell lung cancer: rethinking consolidation therapy. Journal of the National Cancer Center. 2026;6(4):329-344. doi:10.1016/j.jncc.2026.04.006
BibTeX
@article{Tafenzi2026,
author = {Tafenzi, Hassan Abdelilah and Essadi, Ismail and Belbaraka, Rhizlane},
title = {Should we optimise or revise the management of initially unresectable stage III non-small cell lung cancer: rethinking consolidation therapy},
journal = {Journal of the National Cancer Center},
year = {2026},
volume = {6},
number = {4},
pages = {329--344},
doi = {10.1016/j.jncc.2026.04.006}
}
EUVIMED